Who is sponsoring NCT04542954?

NCT04542954 is sponsored by Hamid Al-Essa Organ Transplant Center.

What condition does NCT04542954 study?

NCT04542954 studies Covid19, Kidney Transplant Infection, Risk Factor, Cardiovascular, Immunosuppression, Outcome, Fatal, Graft Failure.

Is NCT04542954 still recruiting?

NCT04542954 is currently completed. Last updated 9 September 2020.

Last reviewed 2020-09-09 · How we verify

NCT04542954: OMC-KTR

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Optimized Management of Covid-19 Positive Kidney Transplant Recipients: Single Center Experience From the Middle East

Completed Last updated 9 September 2020

What this trial tests

trial testing Optimized Management of Covid-19 Positive Kidney Transplant Recipients: Single Center Experience from the Middle East in Covid19 in 104 participants. Completed in 31 August 2020.

Timeline

1 March 2020

Primary endpoint
31 August 2020

31 August 2020

Quick facts

Lead sponsor	Hamid Al-Essa Organ Transplant Center
Status	Completed
Study type	OBSERVATIONAL
Enrollment	104
Start date	1 March 2020
Primary completion	31 August 2020
Estimated completion	31 August 2020
Sites	1 location across Kuwait

Drugs / interventions tested

Optimized Management of Covid-19 Positive Kidney Transplant Recipients: Single Center Experience from the Middle East

Conditions studied

Covid19 — all drugs for Covid19 →
Kidney Transplant Infection — all drugs for Kidney Transplant Infection →
Risk Factor, Cardiovascular — all drugs for Risk Factor, Cardiovascular →
Immunosuppression — all drugs for Immunosuppression →

Sponsor

Hamid Al-Essa Organ Transplant Center

Who can join

Eligibility, any sex, with Covid19 or Kidney Transplant Infection. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

Methods: Out of 2000 kidney transplant recipients in our center in Kuwait, collecting data was started for all COVID-19-positive kidney transplant recipients till August 2020. Clinical features, management details and both patient and graft outcomes were reported.

Publications & conference data

1 peer-reviewed publication reference this trial (live from Europe PMC):

Better outcome of COVID-19 positive kidney transplant recipients during the unremitting stage with optimized anticoagulation and immunosuppression.
AlOtaibi TM, Gheith OA, Abuelmagd MM, Adel M, et al · · 2021 · cited 7× · PMID 33768630 · DOI 10.1111/ctr.14297

Verify or expand the search:

Other recruiting trials for Covid19

Currently open trials in the same condition.

NCT03305341 — Proof-of-Concept Clinical Pharmacology Trial for COVID-19 Antigen Presentation Therapeutic Biologic Mix · EARLY_PHASE1 · active not recruiting
NCT06482138 — Dysfunction of Olfaction After COVID-19 Infection: Morphological and Histomolecular Investigation · NA · recruiting
NCT04924803 — Community Developed Technology-Based Messaging to Increase COVID-19 Vaccine Uptake Among People Who Inject Drugs · NA · active not recruiting
NCT05013632 — COVID-19 International Drug Pregnancy Registry · recruiting
NCT04806061 — Urine Alkalinisation in COVID-19 · NA · active not recruiting

Other Hamid Al-Essa Organ Transplant Center trials

Trials by the same sponsor.

NCT04979195 — Acute Kidney Injury Among COVID-19 Positive Patients · completed
NCT04665830 — PCSK 9 Inhibition as Secondary Prevention in Renal Transplant Patients · Phase 3 · completed
NCT03861637 — Impact of Full Correction of PTA in Renal Transplant Recipients · NA · completed

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT04542954 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Hamid Al-Essa Organ Transplant Center
Last refreshed: 9 September 2020

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04542954.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing